Strong advanced-imaging momentum and accelerating Digital Health ARR drove higher 2026 guidance [12][40][57].
| Quarter | Q1 FY26 |
|---|---|
| Call date | 2026-05-13 |
| Length | 84 minutes |
| EPS | $-0.28 |
| EPS consensus | $-0.14 |
| Revenue | $575.6M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q2 FY26 · Q4 FY25 · Q2 FY25
All RDNT earnings · Back to RDNT overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.